Research paperAssociation of treatment response with obesity and other metabolic risk factors in adults with depressive disorders: Results from a National Depression Cohort study in Korea (the CRESCEND study)
Introduction
Despite the availability of over a dozen first-line antidepressant agents, treatment outcomes remain very disappointing. This deficiency provides a rationale for identifying pre-treatment variables that moderate treatment outcome. Identifying predictors of outcome is essential as the field attempts to replace trial-and-error approaches with precision/personalized medicine. However, no known reliable and robust pre-treatment predictors of outcome in depressive disorders have proven relevant to naturalistic practice (Bennabi et al., 2015).
Previous research has suggested a bidirectional relationship between components of metabolic syndrome (MetS) and depressive disorders. For example, results from epidemiologic studies showed that the incidence of depressive disorders was higher in individuals with components of MetS and vice versa (Kinder et al., 2004, Vanhala et al., 2009). The relationship of MetS and its components with depressive disorders is hypothesized to be mediated by many factors including, but not limited to, neurohormonal, inflammatory, and behavioral factors (McIntyre et al., 2009). Moreover, results from clinical studies also indicate that bipolar disorders and MetS commonly co-occur and that the presence of MetS significantly affects clinical outcomes in bipolar disorders (Kemp et al., 2010). However, relatively fewer studies have evaluated the impact of MetS on treatment response outcomes in depressive disorders.
Sagud et al. (2013) investigated whether MetS, its components, or other cardiovascular risk factors were related to insufficient treatment response in patients with major depressive disorder (MDD). They reported that the prevalence of MetS was similar in those with an insufficient response to antidepressants and those who responded to therapy. They also observed that the distribution of patients exhibiting particular components of MetS (i.e., elevated glucose, elevated triglycerides (TG), low high-density lipoprotein (HDL), elevated blood pressure, and increased waist circumference), or alteration in other cardiovascular risk factors did not significantly differ between patients with and without treatment resistant depression. In a separate study, Vogelzangs et al. (2014) followed patients with depressive disorders (MDD and dysthymia) who were in antidepressant treatment for 2 years and measured baseline values of metabolic and inflammatory factors. The study found that the co-occurrence of four or more metabolic/inflammatory dysregulations in an individual with depressive disorders negatively affected the clinical course and treatment outcome. Several neurobiological processes may even act as mediators in this association. Although several studies have considered the association between metabolic abnormalities and outcomes in the treatment of bipolar disorders (Calkin et al., 2009, Calkin et al., 2015, Ruzickova et al., 2003), relatively few studies have evaluated antidepressant outcomes in depressive disorders wherein MetS is a pre-treatment condition.
This study examined whether Korean adults with MDD who had one or more metabolic conditions exhibited differential therapeutic outcomes with antidepressant therapy.
Section snippets
Study overview
The present study used data gathered by the Clinical Research Center for Depression (CRESCEND), whose design has been detailed elsewhere (Kim et al., 2011). A summary of the study design is presented below.
Between January 2006 and August 2008, CRESCEND enrolled 1183 patients with depressive disorders (major depressive disorder, dysthymic disorder, and depressive disorders not otherwise specified) from 18 South Korean hospitals (16 university hospitals and 2 general hospitals). Enrollment
Characteristics of the sample
Of a total of 1183 patients screened for the CRESCEND study, 541 (45.7%) met the inclusion and exclusion criteria for the analysis described here. Further information from the SCID was available in 492 (90.9%) of these. Of 541 patients, 144 (26.6%) were male, 181 (33.5%) were pre-menopausal females, and 216 (39.9%) were post-menopausal females. Baseline socio-demographic and clinical characteristics of the full sample are summarized in the first column of Table 1. A total of 178 (32.9%)
Discussion
The design and settings of the CRESCEND study were specifically chosen as the data set because the set represents āreal world patientsā receiving treatment under naturalistic conditions. We found that approximately a third of individuals had an insufficient response to treatment, which aligns with treatment results reported elsewhere (Carney and Freedland, 2009, Sagud et al., 2013).
Conclusions
This 1-year naturalistic study found the presence of metabolic abnormalities in patients with depressive disorders to be associated with decreased treatment response to antidepressants. Despite the limitations noted above, this study has important implications for clinicians and for further research. Comorbid obesity or other metabolic conditions might be considered predictors of insufficient treatment response in depressive disorders in clinical practice. Future research that includes
References (62)
- et al.
Risk factors for treatment resistance in unipolar depression: a systematic review
J. Affect. Disord.
(2015) - et al.
Antidepressants in elderly: metaregression of double-blind, randomized clinical trials
J. Affect. Disord.
(2013) - et al.
n-3 fatty acids and the metabolic syndrome
Am. J. Clin. Nutr.
(2006) - et al.
Generalized anxiety disorder is associated with metabolic syndrome in the Vietnam experience study
Biol. Psychiatry
(2009) - et al.
Estrogen selectively increases tryptophan hydroxylase-2 mRNA expression in distinct subregions of rat midbrain raphe nucleus: association between gene expression and anxiety behavior in the open field
Biol. Psychiatry
(2006) - et al.
Improvement within 2 weeks and later treatment outcomes in patients with depressive disorders: the CRESCEND study
J. Affect. Disord.
(2011) - et al.
Race and the insulin resistance syndrome
Semin. Nephrol.
(2013) - et al.
Prevalence of the metabolic syndrome among 40,698 Korean metropolitan subjects
Diabetes Res. Clin. Pract.
(2004) - et al.
Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile
Eur. Neuropsychopharmacol.
(2001) - et al.
Increased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia
Atheroscler. Cancer Obes. Res. Clin. Pract.
(2013)
Streptozotocin-induced diabetes provokes changes in serotonin concentration and on 5-HT1A and 5-HT2 receptors in the rat brain
Life Sci.
Sex differences in response to citalopram: a STAR*D report
J. Psychiatr. Res.
Protection against oxidative stress-induced neuronal cell death-a novel role for RU486
Eur. J. Neurosci.
Obesity: the disease
J. Med. Chem.
Central monoamine dysfunction in diabetes: psychotherapeutic implications: electroanalysis by voltammetry
Acta Physiol. Pharmacol. Latinoam.
Nomenclature and endocrinology of menopause and perimenopause
Expert Rev. Neurother.
Can body mass index help predict outcome in patients with bipolar disorder?
Bipolar Disord.
Insulin resistance and outcome in bipolar disorder
Br. J. Psychiatry
Treatment-resistant depression and mortality after acute coronary syndrome
Am. J. Psychiatry
The emergence of the metabolic syndrome with menopause
J. Clin. Endocrinol. Metab.
Biological variations in depression and anxiety between East and West
CNS Neurosci. Ther.
Insulin resistance, insulin response, and obesity as indicators of metabolic risk
J. Clin. Endocrinol. Metab.
Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimerās disease
Free Radic. Res.
Diabetes, hyperlipidemia, and coronary artery disease
Am. J. Cardiol.
Body fat determination by dual energy X-ray absorptiometry and its relation to body mass index and waist circumference in Hong Kong Chinese
Int. J. Obes. Relat. Metab. Disord.
Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine
J. Clin. Psychiatry
Neuropsychiatric consequences of cardiovascular medications
Dialogues Clin. Neurosci.
Gender differences in metabolic syndrome: a key research issue?
Endocr. Metab. Immune Disord. Drug Targets
Association of metabolically healthy obesity with depressive symptoms: pooled analysis of eight studies
Mol. Psychiatry
Sex differences in human adipose tissues - the biology of pear shape
Biol. Sex Differ.
Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham study
Arterioscler. Thromb. Vasc. Biol.
Cited by (17)
Diabetes and Mental Health
2023, Canadian Journal of DiabetesOverweight in mood disorders: Effects on morbidity and treatment response
2022, Journal of Affective DisordersCitation Excerpt :Studies that investigated demographic variables, including sex, age, and socioeconomic status as moderators between depression and obesity also have yielded inconsistent results (de Wit et al. 2010; Puzhko et al., 2020). Similarly uncertain findings were reported in studies of the impact of BMI on treatment responses in depressive disorders (Papakostas et al., 2006; Khan et al., 2007; Kloiber et al., 2007; Uher et al., 2009; Toups et al., 2013; Lin et al., 2014; McIntyre et al., 2015; Iniesta et al., 2016; Woo et al., 2016a, 2016b; Green et al., 2017; Jha et al., 2018; DreimĆ¼ller et al., 2019; Puzhko et al., 2020). In general, accumulating evidence indicates that obesity and mood disorders are linked and probably share a range of clinical, neurobiological, genetic and environmental factors (Milaneschi et al., 2019).
Excess body weight as a predictor of response to treatment with antidepressants in patients with depressive disorder
2020, Journal of Affective DisordersCitation Excerpt :The relationships between excess weight, sex, and AD response can be even more complex and can depend on a metabolic status for each sex. Woo et al. (2016a) found a significant effect of obesity on response to different AD (SSRI, TCA, etc.) only for post-menopausal women and men with metabolic syndrome. One of the explanations for these results may be lower predictive power of BMI for visceral adiposity in men than in women, especially in men of Asian origin (Vogelzangs et al., 2014).
Affective disorders and physical health, implications of comorbid medical conditions: a non-systematic review
2020, Revista Medica Clinica Las CondesImpact of morbid obesity on treatment outcome in a clinical trial of major depressive disorder
2017, Personalized Medicine in PsychiatryCitation Excerpt :Despite these limitations, our findings are consistent with much of the existing literature suggesting that BMI is a moderating factor that can affect treatment outcome in depression studies. Several well-conducted trials have reported a significant association between a high baseline BMI and a poor response to antidepressant medications in subjects with MDD [1ā8]. In a recent report, Cameron et al.